Generated by AI
Nanobiotix S.A. ADR is a biotechnology company focused on developing nanomedicine-based approaches for cancer treatment. The company’s current activities center on its proprietary physics-based technology platform, which is designed to enhance the effect of radiotherapy by targeting tumor cells more precisely. Its lead therapeutic candidate is being developed for use across several oncology settings, including solid tumors and other difficult-to-treat cancers. Nanobiotix serves the healthcare and life sciences market through research, clinical development, and potential commercialization of advanced cancer therapies, with a business model built around product candidates that integrate with existing treatment protocols. Headquartered in Paris, France, Nanobiotix operates as a clinical-stage company with a focus on oncology innovation and translational medical science.
Website60 rue de Wattignies
Paris, 75012
France
The latest articles about NBTX.
Nanobiotix stock hinges on J&J’s JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX.
Nanobiotix (ENXTPA:NANO) is back in focus after releasing updated Phase 1 data for JNJ-1900, or NBTXR3, in anti-PD-1-resistant advanced primary cutaneous melanoma treated with radiotherapy plus checkpoint inhibitors. The fresh melanoma data has arrived at a time when Nanobiotix has already seen a sharp swing in sentiment, with a 49.71% 7-day share price return and a 48.53% year-to-date share price return, offset by a weaker 90-day share price return of 14.07% and a very large 3-year total...
Summary of May 21's posts. Generated by AI.
Summary of Jul 10's posts. Generated by AI.
Summary of May 17's posts. Generated by AI.
Investors talking about NBTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.